- Home
- SIGA vs OABI Comparison
SIGA vs OABI Comparison
Compare SIGA & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- OABI
- Stock Information
- Founded
- SIGA 1995
- OABI 2012
- Country
- SIGA United States
- OABI United States
- Employees
- SIGA N/A
- OABI N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- OABI Health Care
- Exchange
- SIGA Nasdaq
- OABI Nasdaq
- Market Cap
- SIGA 422.9M
- OABI 236.1M
- IPO Year
- SIGA 1997
- OABI N/A
- Fundamental
- Price
- SIGA $6.74
- OABI $1.98
- Analyst Decision
- SIGA
- OABI Strong Buy
- Analyst Count
- SIGA 0
- OABI 3
- Target Price
- SIGA N/A
- OABI $7.00
- AVG Volume (30 Days)
- SIGA 366.7K
- OABI 644.3K
- Earning Date
- SIGA 07-31-2025
- OABI 08-07-2025
- Dividend Yield
- SIGA 8.94%
- OABI N/A
- EPS Growth
- SIGA N/A
- OABI N/A
- EPS
- SIGA 0.67
- OABI N/A
- Revenue
- SIGA $120,330,310.00
- OABI $26,744,000.00
- Revenue This Year
- SIGA N/A
- OABI N/A
- Revenue Next Year
- SIGA $95.31
- OABI $45.02
- P/E Ratio
- SIGA $10.01
- OABI N/A
- Revenue Growth
- SIGA N/A
- OABI 27.07
- 52 Week Low
- SIGA $4.95
- OABI $1.22
- 52 Week High
- SIGA $12.83
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- SIGA 61.86
- OABI 63.68
- Support Level
- SIGA $6.70
- OABI $1.93
- Resistance Level
- SIGA $6.91
- OABI $2.11
- Average True Range (ATR)
- SIGA 0.21
- OABI 0.13
- MACD
- SIGA 0.01
- OABI 0.02
- Stochastic Oscillator
- SIGA 67.53
- OABI 62.69
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.